Table_3_Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation.xlsx
The capacity of pre-existing immunity to human common coronaviruses (HCoV) to cross-protect against de novo COVID-19is yet unknown. In this work, we studied the sera of 175 COVID-19 patients, 76 healthy donors and 3 intravenous immunoglobulins (IVIG) batches. We found that most COVID-19 patients developed anti-SARS-CoV-2 IgG antibodies before IgM. Moreover, the capacity of their IgGs to react to beta-HCoV, was present in the early sera of most patients before the appearance of anti-SARS-CoV-2 IgG. This implied that a recall-type antibody response was generated. In comparison, the patients that mounted an anti-SARS-COV2 IgM response, prior to IgG responses had lower titres of anti-beta-HCoV IgG antibodies. This indicated that pre-existing immunity to beta-HCoV was conducive to the generation of memory type responses to SARS-COV-2. Finally, we also found that pre-COVID-19-era sera and IVIG cross-reacted with SARS-CoV-2 antigens without neutralising SARS-CoV-2 infectivity in vitro. Put together, these results indicate that whilst pre-existing immunity to HCoV is responsible for recall-type IgG responses to SARS-CoV-2, it does not lead to cross-protection against COVID-19.
History
References
- https://doi.org//10.1001/jama.2020.12839
- https://doi.org//10.1038/s41586-020-2550-z
- https://doi.org//10.1016/j.cell.2020.05.015
- https://doi.org//10.1038/s41586-020-2598-9
- https://doi.org//10.1126/science.abd3871
- https://doi.org//10.1038/s41467-020-19943-y
- https://doi.org//10.1126/sciimmunol.abe5511
- https://doi.org//10.1126/sciimmunol.abe0367
- https://doi.org//10.1056/NEJMc1215489
- https://doi.org//10.1126/sciimmunol.abe0240
- https://doi.org//10.1146/annurev-virology-110615-042301
- https://doi.org//10.1016/S0140-6736%2820%2930251-8
- https://doi.org//10.1101/2020.10.08.20209650
- https://doi.org//10.1038/s41590-020-00826-9
- https://doi.org//10.1126/science.abe1107
- https://doi.org//10.1016/S1473-3099%2820%2930196-1
- https://doi.org//10.1038/s41591-020-0897-1
- https://doi.org//10.1093/cid/ciaa310
- https://doi.org//10.1016/j.immuni.2020.04.023
- https://doi.org//10.1126/scitranslmed.abd2223
- https://doi.org//10.1016/S0140-6736%2820%2932137-1
- https://doi.org//10.1056/NEJMoa2035389
- https://doi.org//10.1056/NEJMoa2034577
- https://doi.org//10.2139/ssrn.3546070
- https://doi.org//10.1371/journal.pmed.0030343
- https://doi.org//10.1001/jama.2020.12607
- https://doi.org//10.1371/journal.pone.0202736
- https://doi.org//10.1016/j.jim.2017.05.005
- https://doi.org//10.1084/jem.2018163501152020c
- https://doi.org//10.1038/sj.mt.6300135
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity